Development of byom-0322 for the prevention and treatment of breast cancer (HR+, her+, and tnbc) metastases and cachexia
Active Project Grant Awarded
- Award ID
- HT94252410158
- Recipient
-
Byomass Inc. UEI N57BMT7GFJG6
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $1,383,586
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 90% complete
- Place of performance
- Sudbury, MA 01776, USA
Award details come from USAspending.gov.
About this award
This federal Project Grant award from the Department of Defense's Defense Health Agency (CFDA 12.420 - Military Medical Research and Development program) provides $1,383,586.00 to Byomass Inc. to support the development of BYOM-0322, a novel biologic agent targeting the TGF-beta superfamily. The purpose is to evaluate BYOM-0322 for the prevention and treatment of breast cancer metastases and cancer cachexia (muscle wasting). This 3-year grant, awarded on February 15, 2024, will fund Byomass Inc.'s research and development efforts to advance this innovative biologic therapy through preclinical and potential early clinical testing. The Military Medical Research and Development program supports a range of biomedical research to improve health outcomes for military service members, veterans, and their families, with a focus on high-impact, transformative projects.
Quick answers
Who received award HT94252410158?
HT94252410158 was awarded to Byomass Inc. by Defense Health Agency (Department of Defense) on February 15, 2024.
How much is award HT94252410158 worth?
$1,383,586 has been obligated on HT94252410158.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award